{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:35:27Z","timestamp":1767792927813,"version":"3.49.0"},"reference-count":44,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Data on asthma with fixed airway obstruction (FAO) are heterogeneous due to different and misleading definitions. Describing the FAO phenotype has significant implications for severe asthma (SA) comprehension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterise SA patients with FAO in the Severe Asthma Network in Italy (SANI) registry at baseline, and to compare with those with reversible airway obstruction (bronchodilator responsiveness, BDR). The potential for re-evaluating FAO or BDR in the follow-up was explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      FAO was defined as a forced expiratory volume in the first second (FEV\n                      <jats:sub>1<\/jats:sub>\n                      )\/forced vital capacity ratio &lt; Lower Limit of Normal (LNN) after a bronchodilator test with an increase in FEV\n                      <jats:sub>1<\/jats:sub>\n                      of &lt;12%\u2009or 200\u2009mL, compared with BDR and no airway obstruction (no-AO). Clinical reported outcomes, including asthma control (ACT), quality of life (AQLQ) and exacerbations (AEs) were collected. The effect of demographic, clinical and biohumoral variables on FAO, BDR and no-AO groups at baseline and during the follow-up was estimated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 354 patients, 190 (53.7%) reported AO with 116 (60.1%) resulting in FAO. The overall FAO rate at enrolment was 32.8%. Compared with BDR, FAO patients had better asthma control (34.5% vs 20.3%, p=0.004), a higher ACT (17.4 vs 15.2, p=0.005) and AQLQ (4.6 vs 3.8, p=0.001) score. FAO patients were less likely to visit the emergency room or be hospitalised than BDR (p=0.050), with no difference in AEs. The effect of airway calibre on fractional exhaled nitric oxide is more likely to cause its lower level within FAO compared with BDR (29.5 vs 46.0 ppb, p=0.04) than a lower T2 burden. A variation from FAO to BDR or no-AO was associated with the Global Initiative for Asthma classification (step 4 vs 5: HR 3.58 (95% CI 1.16 to 11.03)) and the age of asthma onset (30\u201339 vs &lt;20 years: HR 3.94 (95% CI 1.09 to 14.30))<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Stratifying SA patients from the SANI registry reveals an FAO phenotype that expresses different clinical outcomes and biological markers compared to BDR. Over time, FAO may be reversible in late-onset SA with less inhaled corticosteroid treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002992","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:45:18Z","timestamp":1761907518000},"page":"e002992","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Fixed airway obstruction and bronchodilator responsiveness phenotypes in severe asthma population from SANI registry"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3876-8587","authenticated-orcid":false,"given":"Giuseppe","family":"Guida","sequence":"first","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"},{"name":"Severe Asthma, Rare Lung Disease and Respiratory Pathophysiology Unit, San Luigi Gonzaga University Hospital, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy"},{"name":"Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Paggiaro","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sala","sequence":"additional","affiliation":[{"name":"Department of Statistics and Quantitative Methods, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"},{"name":"Department of Medicine and Surgery, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[{"name":"Department of Statistics and Quantitative Methods, Universit\u00e0 degli Studi di Milano-Bicocca, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-5018","authenticated-orcid":false,"given":"Fabio L M","family":"Ricciardolo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, Turin, Italy"},{"name":"Severe Asthma, Rare Lung Disease and Respiratory Pathophysiology Unit, San Luigi Gonzaga University Hospital, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manlio","family":"Milanese","sequence":"additional","affiliation":[{"name":"Pulmonology Unit, Santa Corona Hospital, Pietra Ligure, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026010701514042000_12.1.e002992.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"2026010701514042000_12.1.e002992.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100032","article-title":"Prevalence of severe asthma according to the drug regulatory agency perspective: An Italian experience","volume":"12","author":"Vianello","year":"2019","journal-title":"World Allergy Organ J"},{"key":"2026010701514042000_12.1.e002992.3","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2018.1440868","article-title":"Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults","volume":"5","author":"Porsbjerg","year":"2018","journal-title":"Eur Clin Respir J"},{"key":"2026010701514042000_12.1.e002992.4","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.322"},{"key":"2026010701514042000_12.1.e002992.5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"key":"2026010701514042000_12.1.e002992.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2026010701514042000_12.1.e002992.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.10.053"},{"key":"2026010701514042000_12.1.e002992.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035205"},{"key":"2026010701514042000_12.1.e002992.9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"2026010701514042000_12.1.e002992.10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1164\/rccm.202308-1436OC","article-title":"Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness","volume":"209","author":"Beasley","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701514042000_12.1.e002992.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-023-02835-4","article-title":"Clinical characteristics of obese, fixed airway obstruction, exacerbation-prone phenotype and comorbidities among severe asthma patients: a single-center study","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026010701514042000_12.1.e002992.12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cea.13714","article-title":"Asthma and fixed airflow obstruction: Long-term trajectories suggest distinct endotypes","volume":"51","author":"Smith","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"2026010701514042000_12.1.e002992.13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/jpm12030333","article-title":"Asthma with Fixed Airflow Obstruction: From Fixed to Personalized Approach","volume":"12","author":"Bakakos","year":"2022","journal-title":"JPM"},{"key":"2026010701514042000_12.1.e002992.14","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00191","article-title":"Airway Remodeling in Asthma","volume":"7","author":"Hough","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2026010701514042000_12.1.e002992.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12948-017-0065-4","article-title":"SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma","volume":"15","author":"Senna","year":"2017","journal-title":"Clin Mol Allergy"},{"key":"2026010701514042000_12.1.e002992.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2026010701514042000_12.1.e002992.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026010701514042000_12.1.e002992.18","unstructured":"GINA. 2023. Available: https:\/\/ginasthma.org\/wp-content\/uploads\/2023\/07\/GINA-2023-Full-report-23_07_06-WMS.pdf"},{"key":"2026010701514042000_12.1.e002992.19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2147\/JAA.S377174","article-title":"Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy","volume":"15","author":"Chen","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2026010701514042000_12.1.e002992.20","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14d27.x"},{"key":"2026010701514042000_12.1.e002992.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.01.003"},{"key":"2026010701514042000_12.1.e002992.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1126OC"},{"key":"2026010701514042000_12.1.e002992.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.004"},{"key":"2026010701514042000_12.1.e002992.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.03.049"},{"key":"2026010701514042000_12.1.e002992.25","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.5.2011026"},{"key":"2026010701514042000_12.1.e002992.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0713"},{"key":"2026010701514042000_12.1.e002992.27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2213-2600(22)00185-0","article-title":"Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study","volume":"11","author":"Kole","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026010701514042000_12.1.e002992.28","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00370.2016"},{"key":"2026010701514042000_12.1.e002992.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201602-0419OC"},{"key":"2026010701514042000_12.1.e002992.30","first-page":"222","article-title":"Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA","volume":"10","author":"Hanania","year":"2022","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"key":"2026010701514042000_12.1.e002992.31","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09061155"},{"key":"2026010701514042000_12.1.e002992.32","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/S2213-2600(22)00363-0","article-title":"Bronchodilator reversibility in patients with asthma and persistent airflow limitation","volume":"10","author":"Crisafulli","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026010701514042000_12.1.e002992.33","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00366-6","article-title":"Bronchodilator reversibility in patients with asthma and persistent airflow limitation \u2013 Authors\u2019 reply","volume":"10","author":"Kole","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026010701514042000_12.1.e002992.34","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s12325-019-01062-w","article-title":"Burden of Asthma and Role of 2.5 \u00b5g Tiotropium Respimat\u00ae as an Add-On Therapy: A Systematic Review of Phase 2\/3 Trials","volume":"36","author":"Mansfield","year":"2019","journal-title":"Adv Ther"},{"key":"2026010701514042000_12.1.e002992.35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/ajrccm.158.1.9703005","article-title":"Exhaled nitric oxide (NO) is reduced shortly after bronchoconstriction to direct and indirect stimuli in asthma","volume":"158","author":"de Gouw","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010701514042000_12.1.e002992.36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaip.2023.08.027","article-title":"The Impact of Airway Obstruction on Feno Values in Asthma Patients","volume":"12","author":"Michils","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701514042000_12.1.e002992.37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/arm91010007","article-title":"Asthma and Fixed Airways Obstruction: Real Life Aspects","volume":"91","author":"Buonamico","year":"2023","journal-title":"Adv Respir Med"},{"key":"2026010701514042000_12.1.e002992.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12891-7"},{"key":"2026010701514042000_12.1.e002992.39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/resp.12687","article-title":"Effect of treatment with inhaled corticosteroid on serum periostin levels in asthma","volume":"21","author":"Hoshino","year":"2016","journal-title":"Respirology"},{"key":"2026010701514042000_12.1.e002992.40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00954-2020","article-title":"Looking back to go forward: adherence to inhaled therapy before biologic therapy in severe asthma","volume":"55","author":"Costello","year":"2020","journal-title":"Eur Respir J"},{"key":"2026010701514042000_12.1.e002992.41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02298-2016","article-title":"Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma","volume":"50","author":"Hekking","year":"2017","journal-title":"Eur Respir J"},{"key":"2026010701514042000_12.1.e002992.42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22030998","article-title":"Reticular Basement Membrane Thickness Is Associated with Growth- and Fibrosis-Promoting Airway Transcriptome Profile-Study in Asthma Patients","volume":"22","author":"Bazan-Socha","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026010701514042000_12.1.e002992.43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cea.13714","article-title":"Asthma and fixed airflow obstruction: Long\u2010term trajectories suggest distinct endotypes","volume":"51","author":"Smith","year":"2021","journal-title":"Clin Experimental Allergy"},{"key":"2026010701514042000_12.1.e002992.44","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101056","article-title":"Role of body anthropometry in severe asthmatic patients: Evidences from the Severe Asthma Network in Italy (SANI) registry","volume":"18","author":"Ridolo","year":"2025","journal-title":"World Allergy Organ J"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:53:00Z","timestamp":1767779580000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjresp-2024-002992"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002992","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}